Reporting Manager
Trails Edge Capital Partners, LP
Symbol
SNSE
Shares outstanding
1,272,828 shares
Disclosed Ownership
126,010 shares
Ownership
9.9%
Form type
SCHEDULE 13G
Filing time
25 Feb 2026, 16:15:07 UTC
Date of event
18 Feb 2026

Sponsored

Quoteable Key Fact

"Trails Edge Capital Partners, LP disclosed 9.9% ownership in Sensei Biotherapeutics, Inc. Common Shares, no par value per share (SNSE) on 18 Feb 2026."

Quick Takeaways

  • Trails Edge Capital Partners, LP filed SCHEDULE 13G for Sensei Biotherapeutics, Inc. Common Shares, no par value per share (SNSE).
  • Disclosed ownership: 9.9%.
  • Date of event: 18 Feb 2026.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 25 Feb 2026, 16:15.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (3)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Trails Edge Capital Partners, LP 9.9% 126,010 126,010 0 /s/ Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC
Trails Edge Biotechnology Master Fund, LP 9.9% 126,010 126,010 0 /s/ Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai Ortav Yehudai / Chief Investment Officer of Trails Edge GP, LLC
Ortav Yehudai 9.9% 126,010 126,010 0 /s/ Ortav Yehudai Ortav Yehudai / Individual